Suhas Sampat Kharat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Suhas Sampat Kharat has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Shyam K. Sharan
Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, USA
3 shared publications - Mansoor Hussain
National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India
2 shared publications - Sagar Sengupta
Biotechnology Research and Innovation Council—National Institute of Immunology (BRIC-NII), Aruna Asaf Ali Marg, New Delhi, India
2 shared publications - Sandra Burkett
Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, USA
2 shared publications Satheesh K. Sengodan
Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702 USA
2 shared publicationsA P Damodaran
National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India
1 shared publication
Latest Publications
- Open Access
- 19 June 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (7) , 110393
5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells
- 19 June 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (7) , 110393
Open Access5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells
- Open Access
- 18 November 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (11) , 1-10
Characterization of BRCA2 R3052Q variant in mice supports its functional impact as a low-risk variant
Pathogenic variants in BRCA2 are known to significantly increase the lifetime risk of developing breast and ovarian cancers. Sequencing-based genetic testing has resulted in the identification of thousands of BRCA2 variants that are considered to be variants of uncertain significance (VUS) because the disease risk associated with them is unknown. One such variant is p.Arg3052Gln, which has conflicting interpretations of pathogenicity in the ClinVar variant database. Arginine at position 3052 in BRCA2 plays an important role in stabilizing its C-terminal DNA binding domain. We have generated a knock-in mouse model expressing this variant to examine its role on growth and survival in vivo. Homozygous as well as hemizygous mutant mice are viable, fertile and exhibit no overt phenotype. While we did not observe any hematopoietic defects in adults, we did observe a marked reduction in the in vitro proliferative ability of fetal liver cells that were also hypersensitive to PARP inhibitor, olaparib. In vitro studies performed on embryonic and adult fibroblasts derived from the mutant mice showed significant reduction in radiation induced RAD51 foci formation as well as increased genomic instability after mitomycin C treatment. We observed mis-localization of a fraction of R3052Q BRCA2 protein to the cytoplasm which may explain the observed in vitro phenotypes. Our findings suggest that BRCA2 R3052Q should be considered as a hypomorphic variant.
- 18 November 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (11) , 1-10
Open AccessCharacterization of BRCA2 R3052Q variant in mice supports its functional impact as a low-risk variant
Pathogenic variants in BRCA2 are known to significantly increase the lifetime risk of developing breast and ovarian cancers. Sequencing-based genetic testing has resulted in the identification of thousands of BRCA2 variants that are considered to be variants of uncertain significance (VUS) because the disease risk associated with them is unknown. One such variant is p.Arg3052Gln, which has conflicting interpretations of pathogenicity in the ClinVar variant database. Arginine at position 3052 in BRCA2 plays an important role in stabilizing its C-terminal DNA binding domain. We have generated a knock-in mouse model expressing this variant to examine its role on growth and survival in vivo. Homozygous as well as hemizygous mutant mice are viable, fertile and exhibit no overt phenotype. While we did not observe any hematopoietic defects in adults, we did observe a marked reduction in the in vitro proliferative ability of fetal liver cells that were also hypersensitive to PARP inhibitor, olaparib. In vitro studies performed on embryonic and adult fibroblasts derived from the mutant mice showed significant reduction in radiation induced RAD51 foci formation as well as increased genomic instability after mitomycin C treatment. We observed mis-localization of a fraction of R3052Q BRCA2 protein to the cytoplasm which may explain the observed in vitro phenotypes. Our findings suggest that BRCA2 R3052Q should be considered as a hypomorphic variant.
- 18 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (645)
Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability
Loss of DNA demethylase TET2 protects stalled replication forks from degradation and confers chemoresistance.
- 18 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (645)
Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability
Loss of DNA demethylase TET2 protects stalled replication forks from degradation and confers chemoresistance.
- Open Access
- 1 September 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (36) , 13224-13232
Abrogation of FBW7α-dependent p53 degradation enhances p53’s function as a tumor suppressor
- 1 September 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (36) , 13224-13232
Open AccessAbrogation of FBW7α-dependent p53 degradation enhances p53’s function as a tumor suppressor
- 1 June 2015
- Published by Springer Nature in Oncogene
- Vol. 35 (8) , 1025-1038
Mitotic phosphorylation of Bloom helicase at Thr182 is required for its proteasomal degradation and maintenance of chromosomal stability
Mutations in Bloom helicase (BLM) lead to Bloom Syndrome (BS). BS is characterized by multiple clinical manifestations including predisposition to a wide spectrum of cancers. Studies have revealed the mechanism of BLM recruitment after stalled replication and its role during the repair of DNA damage. We now provide evidence that BLM undergoes K48-linked ubiquitylation and subsequent degradation during mitosis due to the E3 ligase, Fbw7α. Fbw7α carries out its function after GSK3β- and CDK2/cyclin A2-dependent phosphorylation events on Thr171 and Ser175 of BLM which lies within a well-defined phosphodegron, a sequence which is conserved in all primates. Phosphorylation on BLM Thr171 and Ser175 depends on prior phosphorylation at Thr182 by Chk1/Chk2. Thr182 phosphorylation not only controls BLM ubiquitylation and degradation during mitosis but is also a determinant for its localization on the ultrafine bridges. Consequently lack of Thr182 phosphorylation leads to multiple manifestations of chromosomal instability including increased levels of DNA damage, lagging chromatin, micronuclei formation, breaks and quadriradials. Hence Thr182 phosphorylation on BLM has two functions—it regulates BLM turnover during mitosis and also helps to maintain the chromosomal stability.
- 1 June 2015
- Published by Springer Nature in Oncogene
- Vol. 35 (8) , 1025-1038
Mitotic phosphorylation of Bloom helicase at Thr182 is required for its proteasomal degradation and maintenance of chromosomal stability
Mutations in Bloom helicase (BLM) lead to Bloom Syndrome (BS). BS is characterized by multiple clinical manifestations including predisposition to a wide spectrum of cancers. Studies have revealed the mechanism of BLM recruitment after stalled replication and its role during the repair of DNA damage. We now provide evidence that BLM undergoes K48-linked ubiquitylation and subsequent degradation during mitosis due to the E3 ligase, Fbw7α. Fbw7α carries out its function after GSK3β- and CDK2/cyclin A2-dependent phosphorylation events on Thr171 and Ser175 of BLM which lies within a well-defined phosphodegron, a sequence which is conserved in all primates. Phosphorylation on BLM Thr171 and Ser175 depends on prior phosphorylation at Thr182 by Chk1/Chk2. Thr182 phosphorylation not only controls BLM ubiquitylation and degradation during mitosis but is also a determinant for its localization on the ultrafine bridges. Consequently lack of Thr182 phosphorylation leads to multiple manifestations of chromosomal instability including increased levels of DNA damage, lagging chromatin, micronuclei formation, breaks and quadriradials. Hence Thr182 phosphorylation on BLM has two functions—it regulates BLM turnover during mitosis and also helps to maintain the chromosomal stability.